Rapid Medical's Intracranial Tigertriever 13 Receives CE Mark Approval
July 31, 2018—Rapid Medical announced that it has received European CE Mark approval for the Tigertriever 13, the next-generation in the company's Tigertriever family of adjustable, fully visible clot retrievers to treat ischemic stroke patients. The company is launching the Tigertriever 13 in Europe during Q3 2018 and advised that the first patients have been treated successfully with the device.
The Tigertriever 13, which is designed to treat medium vessel occlusions (MVOs), is delivered through a neurovascular microcatheter with a soft distal outer diameter of 1.3 F to recanalize intracranial vessels of 1 to 2.5 mm.
In the company's announcement, Prof. René Chapot, MD, commented, "Tigertriever 13 is a very important addition to the ischemic stroke device market. For the first time ever, we have a tool that is dedicated to more distal occlusions. These occlusions can have a dramatic disabling effect on patients and until now there was little to be done for them. Using the Tigertriever 13, we were able to retrieve clots from an MVO that was not treatable until now." Prof. Chapot is Head of the Department of Neuroradiology & Radiology at Krupp Krankenhaus, in Essen, Germany.
Jeffrey Saver, MD, added, "We know that endovascular therapy is the best option for large vessel occlusions. The Tigertriever 13 will further extend this powerful treatment for acute ischemic stroke to patients with MVOs." Dr. Saver is Professor of Neurology and Director of the comprehensive stroke center at the David Geffen School of Medicine of UCLA, in Los Angeles, California.